| BAX |
Report |
Adjusted EPS |
BEAT |
pred ~$0.37 vs. cons $0.36 |
MEDIUM |
| BAX |
Report |
Revenue |
IN-LINE |
pred ~$2.74B vs. cons $2.75B |
MEDIUM |
| BAX |
Report |
Organic revenue growth |
MISS |
pred ~-2.0% vs. cons -0.5% |
MEDIUM |
| BAX |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide ~$1.85-$2.05 vs. cons $1.95 (FY26) |
MEDIUM |
| BAX |
Guide |
FY26 organic revenue growth |
UNCHANGED |
guide ~0.0% vs. cons 0.0% (FY26) |
MEDIUM |
| BAX |
Guide |
FY26 adjusted operating margin |
UNCHANGED |
guide ~13.0%-14.0% vs. cons 13.5% (FY26) |
MEDIUM |
| BAX |
Guide |
2H26 adjusted operating-margin expansion versus 1H26 |
UNCHANGED |
guide ~500 bps vs. cons 500 bps (2H26 vs. 1H26) |
LOW |
| BAX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.5% |
— |
MEDIUM |
| BAX |
Return |
5-day cumulative residual |
-4.5% (FOLLOW-THROUGH) |
A modest EPS beat is unlikely to offset a weaker organic-sales print and the still-demanding ~500-bp 2H-versus-1H margin bridge. Even with FY26 EPS held at ~$1.95 midpoint versus ~$1.95 consensus, investors are likely to lower confidence in the ~$1.23 implied 2H EPS requirement versus ~$1.23 currently embedded, pressuring out-period estimates and extending the initial move. |
MEDIUM |